Menstrual Disorders Practice Questions

Q: A 35-year-old multigravida aborted 5 months back at 17 weeks of gestation. She has not had her periods yet, and her urine pregnancy test is negative. An estrogen-progesterone withdrawal test is also negative. What is the likely diagnosis?

Asherman syndrome. **Explanation:** The patient presents with **secondary amenorrhea** following a mid-trimester abortion. The key to this diagnosis lies in the **negative Estrogen-Progesterone (E+P) withdrawal test**. 1. **Why Asherman Syndrome is correct:** A negative E+P withdrawal test indicates that even with adequate hormonal stimulation, the endometrium fails to bleed. This signifies an **outflow tract obstruction** or **endometrial destruction**. In the clinical context of a recent pregnancy-related evacuation (abortion at 17 weeks), the most likely cause is intrauterine adhesions (synechiae) that have obliterated the uterine cavity, known as Asherman Syndrome. 2. **Why other options are incorrect:** * **Anovulation:** In anovulation, the endometrium is primed with estrogen but lacks progesterone. A progesterone challenge would be negative, but an **E+P challenge would be positive** (bleeding would occur). * **Pituitary Failure (Secondary Hypogonadism) & Ovarian Failure (Primary Hypogonadism):** In both conditions, the uterus and outflow tract are intact, but endogenous hormones are deficient. Therefore, providing exogenous Estrogen and Progesterone would result in a **positive withdrawal bleed**. **High-Yield Clinical Pearls for NEET-PG:** * **Step-wise approach to Amenorrhea:** 1. Rule out pregnancy (UPT) → 2. Progesterone Challenge → 3. E+P Challenge → 4. FSH/LH levels. * **Gold Standard Investigation** for Asherman Syndrome: **Hysteroscopy** (Diagnostic and Therapeutic). * **HSG Finding:** Characterized by "honeycomb appearance" or irregular filling defects. * **Most common cause:** Vigorous curettage of a pregnant or postpartum uterus (due to the softness of the basal layer of the endometrium).

Q: Heavy menstrual bleeding is assessed by all of the following EXCEPT:

Blood loss more than 120 ml. **Explanation:** Heavy Menstrual Bleeding (HMB) is clinically defined as excessive menstrual blood loss which interferes with a woman's physical, social, emotional, and/or material quality of life. **1. Why Option D is the Correct Answer:** The classic objective definition of HMB (formerly menorrhagia) is a total blood loss of **more than 80 ml** per cycle. Option D states "more than 120 ml," which is an incorrect threshold for the standard definition. While 120 ml is indeed heavy, it is not the diagnostic cutoff used in medical literature or clinical guidelines. **2. Analysis of Incorrect Options (Criteria for HMB):** * **Option A:** Passing large clots (greater than 1 inch or 2.5 cm) is a reliable clinical indicator of heavy flow, as the natural anticoagulants in the uterus cannot keep up with the volume of bleeding. * **Option B:** A drop in hemoglobin (Anemia) is a common objective consequence of chronic HMB. If a patient presents with iron deficiency anemia and heavy periods, it confirms the clinical significance of the blood loss. * **Option C:** Prolonged menses lasting more than 7 days is one of the primary criteria used to define HMB/menorrhagia. **3. NEET-PG High-Yield Pearls:** * **Gold Standard Measurement:** The alkaline hematin method is the gold standard for objective measurement but is only used in research. * **PBAC Score:** The Pictorial Blood Loss Assessment Chart (PBAC) is used in clinics; a score **>100** indicates HMB. * **PALM-COEIN:** This is the FIGO classification for the etiology of Abnormal Uterine Bleeding (AUB). * **First-line Investigation:** Transvaginal Ultrasound (TVUS). * **Medical Management:** Levonorgestrel Intrauterine System (LNG-IUS) is the first-line treatment for HMB.

Q: Withdrawal bleeding with progesterone is seen in an otherwise amenorrheic woman due to which of the following?

Anovulation. **Explanation:** The **Progesterone Challenge Test (PCT)** is a fundamental diagnostic tool in amenorrhea. For withdrawal bleeding to occur after progesterone administration, two physiological prerequisites must be met: 1. **Endometrial Priming:** The endometrium must have been previously exposed to endogenous **estrogen**, causing it to proliferate. 2. **Patent Outflow Tract:** There must be a functional uterus, cervix, and vagina. In **Anovulation (Option B)**, the ovaries produce estrogen (leading to endometrial proliferation), but because ovulation does not occur, no corpus luteum is formed and no progesterone is produced. This results in a state of "unopposed estrogen." Administering exogenous progesterone and then stopping it mimics the natural decline of the corpus luteum, causing the primed endometrium to shed (withdrawal bleed). **Why other options are incorrect:** * **Hypogonadotropic Hypogonadism (Option A):** Low FSH/LH levels lead to minimal estrogen production. Without estrogen to prime the endometrium, progesterone cannot cause a withdrawal bleed. * **Ovarian Failure (Option C):** In Premature Ovarian Failure, the follicles are depleted. Estrogen levels are critically low, resulting in a negative PCT. * **Tuberculous Endometritis (Option D):** This causes destruction of the endometrial lining or synechiae (Asherman-like syndrome). Even with adequate hormones, there is no functional tissue to shed. **NEET-PG High-Yield Pearls:** * **Positive PCT:** Confirms anovulation (e.g., PCOS) and implies adequate endogenous estrogen. * **Negative PCT:** Indicates either **low estrogen** (Hypothalamic/Ovarian failure) or an **outflow tract obstruction** (Asherman’s/Mulleris agenesis). * The next step after a negative PCT is the **Estrogen-Progesterone Challenge Test** to differentiate between low estrogen and anatomical defects.

Q: A 48-year-old woman, P2L2, with menorrhagia, diagnosed with adenomyosis, is not responding to medical management with NSAIDs and hormonal therapy. What is the next step in management?

Hysteroscopy biopsy. **Explanation:** The correct answer is **D. Hysteroscopy biopsy**. **1. Why Hysteroscopy Biopsy is the Correct Next Step:** In a 48-year-old woman presenting with Abnormal Uterine Bleeding (AUB) that is refractory to medical management, the primary clinical priority is to **exclude endometrial hyperplasia or malignancy**. According to FIGO and ACOG guidelines, any woman over the age of 45 with AUB (or younger with risk factors) must undergo endometrial sampling. Even if a diagnosis of adenomyosis has been made clinically or via ultrasound, the failure of medical therapy necessitates a pathological evaluation of the endometrium before proceeding to definitive surgical interventions. **2. Why Other Options are Incorrect:** * **A. Mirena (LNG-IUD):** While Mirena is an excellent second-line medical treatment for adenomyosis, it should not be initiated in a perimenopausal woman with persistent bleeding until the endometrium has been sampled to rule out malignancy. * **B. GnRH Analogues:** These are generally used as a short-term "bridge" to surgery or to shrink the uterus; they do not provide a definitive diagnosis and are not the immediate next step when malignancy needs to be excluded. * **C. Hysterectomy:** This is the definitive treatment for adenomyosis. However, performing a major surgery without first ruling out endometrial cancer via biopsy is considered poor clinical practice, as the presence of malignancy would alter the surgical approach (e.g., staging, lymphadenectomy). **Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis for Adenomyosis:** Histopathology (post-hysterectomy). * **Investigation of Choice (Imaging):** MRI (shows thickening of the Junctional Zone >12mm). * **Rule of Thumb:** In any perimenopausal/postmenopausal bleeding, **"Rule out Cancer first"** via Endometrial Biopsy or D&C. * **Definitive Treatment:** Hysterectomy is the only cure for adenomyosis.

Q: Which of the following IUDs is used for patients with menorrhagia?

Progestase (Levonorgestrel). **Explanation:** The correct answer is **D. Progestase (Levonorgestrel)**. **Why it is correct:** The Levonorgestrel-releasing Intrauterine System (LNG-IUS), commonly known by brand names like Mirena or Progestasert/Progestase, is the only IUD indicated for the treatment of **menorrhagia** (heavy menstrual bleeding). It works by releasing a low dose of progestogen directly into the uterine cavity, which causes profound **endometrial atrophy** and thinning. This leads to a significant reduction in menstrual blood loss (up to 90%) and often results in amenorrhea. It is considered a first-line medical management for Idiopathic Menorrhagia and is also used in cases of adenomyosis and endometriosis. **Why the other options are incorrect:** * **A, B, and C (CuT 250, Multiload, Nova T):** These are all **Copper-containing IUDs**. Copper IUDs are non-hormonal and work primarily by causing a sterile inflammatory response in the endometrium. A well-known side effect of copper IUDs is an **increase in menstrual blood loss** and dysmenorrhea. Therefore, they are contraindicated in patients already suffering from menorrhagia. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of LNG-IUS:** Thickens cervical mucus (primary), causes endometrial atrophy, and inhibits sperm motility. * **Life Span:** LNG-IUS (Mirena) is typically effective for 5–8 years. * **Non-contraceptive benefits:** Reduces the risk of Pelvic Inflammatory Disease (PID) due to thickened cervical mucus and protects against endometrial hyperplasia/cancer. * **Ideal Candidate:** A woman with heavy periods who also requires long-term, reversible contraception.

Q: A 34-year-old woman presents with abnormal uterine bleeding. Which of the following is the LEAST likely cause of abnormal bleeding in this age group?

Endometrial atrophy. **Explanation:** The correct answer is **Endometrial atrophy**. Abnormal Uterine Bleeding (AUB) in reproductive-age women (typically 15–45 years) is classified by the **FIGO PALM-COEIN** criteria. In a 34-year-old woman, the uterus is under the constant influence of estrogen, which promotes endometrial proliferation. **Endometrial atrophy** occurs due to a state of estrogen deficiency, making it the hallmark cause of postmenopausal bleeding. It is highly unlikely in a woman of reproductive age unless there is severe premature ovarian insufficiency or prolonged use of certain hormonal contraceptives (e.g., DMPA). **Analysis of Incorrect Options:** * **Adenomyosis (A):** Common in women in their 30s and 40s, typically presenting with heavy menstrual bleeding (HMB) and dysmenorrhea. * **Fibroids (B):** Leiomyomas are the most common benign tumors in women of reproductive age and a leading cause of HMB and pelvic pressure. * **Polyps (C):** Endometrial polyps are frequent causes of intermenstrual bleeding and AUB in the premenopausal age group. **NEET-PG High-Yield Pearls:** * **Most common cause of AUB in postmenopausal women:** Endometrial atrophy (60-80%), though malignancy must always be ruled out. * **Most common cause of AUB in adolescents:** Anovulation due to an immature Hypothalamic-Pituitary-Ovarian (HPO) axis. * **Gold Standard Investigation for AUB:** Hysteroscopy (allows direct visualization and directed biopsy). * **First-line investigation:** Transvaginal Ultrasound (TVS).

Q: In a patient with secondary amenorrhea who does not experience withdrawal bleeding after estrogen and progesterone administration, the underlying issue is most likely at which level?

Endometrium. This question tests the understanding of the **stepwise evaluation of secondary amenorrhea**. ### **Explanation of the Correct Answer** The **Estrogen-Progesterone Challenge Test** is the final step in localizing the cause of amenorrhea. 1. **Estrogen** is given to prime the endometrium (proliferation). 2. **Progesterone** is then given to induce secretory changes. 3. Upon withdrawal, if the outflow tract is patent and the endometrium is functional, **withdrawal bleeding must occur.** If there is **no bleeding** after this combined therapy, it indicates that the target organ—the **endometrium**—is either absent, damaged, or the outflow tract is obstructed. This is characteristic of **Asherman’s Syndrome** (intrauterine synechiae) or **Müllerian agenesis** (though the latter usually presents as primary amenorrhea). ### **Why Other Options are Incorrect** * **A & B (Pituitary & Hypothalamus):** If the defect were at the level of the brain (low GnRH or FSH/LH), the endometrium would still be responsive. Providing exogenous estrogen and progesterone bypasses the brain, so these patients **would** experience withdrawal bleeding. * **C (Ovary):** In premature ovarian failure, the endogenous estrogen is low, but the endometrium remains responsive. These patients **would** bleed after receiving exogenous hormones. ### **High-Yield NEET-PG Clinical Pearls** * **Step 1:** Rule out pregnancy (most common cause of secondary amenorrhea). * **Step 2:** Progesterone Challenge Test (PCT). If bleeding occurs = **Anovulation** (e.g., PCOS). * **Step 3:** If PCT is negative, perform the Estrogen + Progesterone Challenge. * **Negative E+P Challenge:** Confirms **End-organ failure** (Asherman’s Syndrome). * **Gold Standard Investigation** for Asherman’s Syndrome: **Hysteroscopy.**

Q: What is the preferred method of contraception for managing menorrhagia?

Levonorgestrel-releasing IUD (LNG IUD). ### Explanation **Correct Answer: C. Levonorgestrel-releasing IUD (LNG IUD)** The **LNG IUD (Mirena)** is the preferred contraceptive method for managing menorrhagia (Heavy Menstrual Bleeding) because it acts directly on the endometrium. It releases a steady dose of levonorgestrel, which leads to **endometrial atrophy** and down-regulation of estrogen receptors. This results in a significant reduction in menstrual blood loss (up to 90% within 3–6 months) and often leads to amenorrhea. It is considered a first-line medical management for idiopathic menorrhagia, often preventing the need for surgical interventions like hysterectomy. **Analysis of Incorrect Options:** * **A. Modified IUD:** This is a vague term. While some modified frames exist, they do not possess the specific hormonal properties required to treat menorrhagia. * **B. Cu-T (Copper T):** This is **contraindicated** in patients with menorrhagia. A common side effect of copper-bearing IUDs is an *increase* in menstrual blood loss and dysmenorrhea due to a local inflammatory response. * **D. Condom:** While an effective barrier contraceptive, it has no hormonal influence on the menstrual cycle and provides no therapeutic benefit for heavy bleeding. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard:** LNG IUD is the most effective non-surgical treatment for Heavy Menstrual Bleeding (HMB). * **Pearl:** It is also used in the management of endometriosis, adenomyosis, and endometrial hyperplasia without atypia. * **Failure Rate:** The Pearl Index of LNG IUD is approximately **0.2**, making it as effective as sterilization. * **Life Span:** The standard LNG IUD (52mg) is FDA-approved for **8 years** for contraception (though often cited as 5 years for menorrhagia).

Q: Massive painless vaginal bleeding after a 6-8 week period of amenorrhea, in a premenopausal woman, is suggestive of?

Metropathia haemorrhagica. **Explanation:** **Metropathia Haemorrhagica (Schroeder’s Disease)** is a specialized form of Dysfunctional Uterine Bleeding (DUB) typically seen in perimenopausal women. It occurs due to **persistent unovulation**. 1. **Why it is correct:** The pathophysiology involves a single follicle that matures but fails to rupture (no ovulation). This leads to a state of **unopposed estrogen** with an absolute absence of progesterone. The estrogen causes the endometrium to proliferate excessively (hyperplasia). Eventually, the estrogen levels fluctuate or the endometrium outgrows its blood supply, leading to **painless, massive, and prolonged bleeding** following a period of amenorrhea (usually 6-8 weeks). This classic clinical triad is often referred to as the "Metropathic pattern." 2. **Why other options are incorrect:** * **Irregular Ripening:** Caused by poor corpus luteum function (progesterone deficiency). It presents as premenstrual spotting, not massive bleeding after amenorrhea. * **Irregular Shedding (Halban Disease):** Caused by a persistent corpus luteum. It presents as prolonged, heavy bleeding, but the bleeding starts *on time* with the expected menses, not after a period of amenorrhea. * **Endometrial Carcinoma:** While it causes abnormal bleeding in older women, it typically presents as postmenopausal bleeding or intermenstrual bleeding, rather than the specific cyclic pattern of amenorrhea followed by flooding. **High-Yield Clinical Pearls for NEET-PG:** * **Characteristic Finding:** On D&C, the endometrium shows **Swiss-Cheese Hyperplasia** (cystic glandular hyperplasia). * **Ovarian Finding:** Presence of a follicular cyst (Amnestic follicle) on one ovary; the other ovary is usually small/atrophic. * **Uterine Finding:** The uterus is often symmetrically enlarged (myohyperplasia) due to prolonged estrogen stimulation.

Q: Which of the following is NOT a feature of Metropathia haemorrhagica?

Occurs in younger women. **Explanation:** **Metropathia Haemorrhagica** (also known as Schroeder’s Disease) is a specific form of Abnormal Uterine Bleeding (AUB) associated with anovulation. **1. Why Option A is the correct answer:** Metropathia haemorrhagica typically occurs in **perimenopausal women** (women in their 40s), not younger women. The underlying pathology is the persistence of an unruptured Graafian follicle, leading to a prolonged follicular phase without ovulation. This results in a period of amenorrhea (usually 6–8 weeks) followed by heavy, painless bleeding. **2. Analysis of incorrect options:** * **B. Uterus is bulky:** Due to the continuous, unopposed stimulation of estrogen without the counter-effect of progesterone (since no corpus luteum is formed), the myometrium undergoes hypertrophy, making the uterus feel symmetrically bulky (myometrial hyperplasia). * **C. Menorrhagia:** The hallmark clinical presentation is heavy, prolonged, and painless bleeding. Because the endometrium outgrows its blood supply in the absence of progesterone, it sheds irregularly and profusely. * **D. Endometrial hyperplasia:** Continuous estrogen causes the endometrium to become hyperplastic. Classically, this presents as **Swiss-cheese endometrium** (Cystoglandular hyperplasia), where glands of varying sizes are seen on histopathology. **NEET-PG High-Yield Pearls:** * **Classic Triad:** Amenorrhea (short period) → Followed by profuse, painless bleeding → In a perimenopausal woman. * **Ovarian finding:** Presence of a follicular cyst (unruptured follicle) and absence of corpus luteum. * **Histology:** "Swiss-cheese" appearance of the endometrium. * **Treatment of choice:** Dilatation and Curettage (D&C) serves both a diagnostic and therapeutic purpose (to stop the bleeding).

Question 1

A 35-year-old multigravida aborted 5 months back at 17 weeks of gestation. She has not had her periods yet, and her urine pregnancy test is negative. An estrogen-progesterone withdrawal test is also negative. What is the likely diagnosis?

Accepted Answer

Asherman syndrome

Answer

Pituitary failure

Answer

Ovarian failure

Answer

Anovulation

Question 2

Heavy menstrual bleeding is assessed by all of the following EXCEPT:

Accepted Answer

Blood loss more than 120 ml

Answer

Passing clots more than 1 inch in diameter

Answer

Hemoglobin concentration below 12 g/dL

Answer

Menses lasting longer than 7 days

Question 3

Withdrawal bleeding with progesterone is seen in an otherwise amenorrheic woman due to which of the following?

Accepted Answer

Anovulation

Answer

Hypogonadotropic hypogonadism

Answer

Ovarian failure

Answer

Tuberculous endometritis

Question 4

A 48-year-old woman, P2L2, with menorrhagia, diagnosed with adenomyosis, is not responding to medical management with NSAIDs and hormonal therapy. What is the next step in management?

Accepted Answer

Hysteroscopy biopsy

Answer

Mirena (LNG IUD) insertion

Answer

GnRH analogues

Answer

Hysterectomy

Question 5

Which of the following IUDs is used for patients with menorrhagia?

Accepted Answer

Progestase (Levonorgestrel)

Answer

CuT 250

Answer

Multiload

Answer

Nova T

Question 6

A 34-year-old woman presents with abnormal uterine bleeding. Which of the following is the LEAST likely cause of abnormal bleeding in this age group?

Accepted Answer

Endometrial atrophy

Answer

Adenomyosis

Answer

Fibroids

Answer

Polyps

Question 7

In a patient with secondary amenorrhea who does not experience withdrawal bleeding after estrogen and progesterone administration, the underlying issue is most likely at which level?

Accepted Answer

Endometrium

Answer

Pituitary

Answer

Hypothalamus

Answer

Ovary

Question 8

What is the preferred method of contraception for managing menorrhagia?

Accepted Answer

Levonorgestrel-releasing IUD (LNG IUD)

Answer

Modified IUD

Answer

Cu-T

Answer

Condom

Question 9

Massive painless vaginal bleeding after a 6-8 week period of amenorrhea, in a premenopausal woman, is suggestive of?

Accepted Answer

Metropathia haemorrhagica

Answer

Irregular ripening

Answer

Irregular shedding (Halban Disease)

Answer

Endometrial carcinoma

Question 10

Which of the following is NOT a feature of Metropathia haemorrhagica?

Accepted Answer

Occurs in younger women

Answer

Uterus is bulky

Answer

Menorrhagia

Answer

Endometrial hyperplasia

Menstrual Disorders — MCQs

Menstrual Disorders — MCQs

On this page

Practice by Chapter

Want unlimited practice?